Key clinical point: A meta-analysis of three studies involving the 31-gene expression profile test showed it accurately predicts recurrence-free, distant metastasis-free, and melanoma-specific survival.
Major finding: There was a 2.96 increased risk of recurrent metastases and a 2.88 increased risk for distant metastases for class 2B tumors.
Study details: A meta-analysis of 1,268 patients with class I through class III melanoma.
Disclosures: Dr. Greenhaw reports a pending relationship with Castle Biosciences.
Greenhaw BN et al. AAD 19. Session F055, Abstract 11370.